Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
about
Sunitinib in solid tumorsVascular endothelial growth factor receptor-2 in breast cancer.Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.Models for prevention and treatment of cancer: problems vs promises.Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine.Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue.The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK).[Principles and method of action of targeted therapies].Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors.Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
P2860
Q28245467-F71D7102-83FA-452E-842A-940A655D51D3Q33912620-FB0988C9-966B-4726-9C0C-9E81C149B669Q34473476-4F80D81D-0FB8-499A-90D2-31DFD3C296B2Q36526512-F2FDC7F2-A1C2-4068-AE61-C78B48793961Q37066917-7317A843-0AF2-440D-8E38-E69A7870F661Q37356273-5F2343C3-962C-47AB-AAF7-66997A880028Q37848180-1672C228-0BA0-4E7C-9F40-939491FDA6A8Q38598277-F2390544-CA84-43AB-A55F-B39136EB13C8Q38714028-1F1E268A-0772-4B7D-96CE-C99FE1EE6D6FQ39301529-1D1B95D3-741A-4F6B-AE9D-B6D0A8920CBAQ39499521-D4910751-7871-478A-B33D-F9BB229C37EFQ42726949-9296396A-6285-4ADE-A65A-32831C9C5D52Q42810614-4A6C00F4-248F-4B85-9A15-BD508CBF18BAQ43179458-524596EF-6B2D-4A1B-A383-E403DAFF3F30Q51623284-011A0968-06AF-4F6A-907A-8813B80791A3Q55061286-50AE7016-0442-4FD7-9607-C79A4CFD05F7
P2860
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activity of SU11248, a multita ...... nd various other solid tumors.
@en
type
label
Activity of SU11248, a multita ...... nd various other solid tumors.
@en
prefLabel
Activity of SU11248, a multita ...... nd various other solid tumors.
@en
P1476
Activity of SU11248, a multita ...... nd various other solid tumors.
@en
P2093
Aristidis Polyzos
P304
P356
10.1016/J.JSBMB.2007.09.004
P577
2007-09-07T00:00:00Z